PSS22 - Secukinumab Significantly Reduces Work Impairment and Indirect Costs Compared To Ustekinumab and Etanercept In The United Kingdom
- Resource Type
- Abstract
- Source
- In
Value in Health October-November 2017 20(9):A804-A804 - Subject
- Language
- ISSN
- 1098-3015